ASCLF (Ascletis Pharma) Common Stock : $0.10 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Common Stock?

Ascletis Pharma's quarterly common stock declined from Dec. 2023 ($0.10 Mil) to Jun. 2024 ($0.10 Mil) but then stayed the same from Jun. 2024 ($0.10 Mil) to Dec. 2024 ($0.10 Mil).

Ascletis Pharma's annual common stock declined from Dec. 2022 ($0.11 Mil) to Dec. 2023 ($0.10 Mil) and declined from Dec. 2023 ($0.10 Mil) to Dec. 2024 ($0.10 Mil).

Ascletis Pharma Common Stock Historical Data

The historical data trend for Ascletis Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Common Stock Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.12

0.11

0.10

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial												0.11	0.10	0.10	0.10	0.10

Ascletis Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

01672:Hong Kong 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.